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OBJECTIVE — Despite higher rates of nephropathy, calciﬁed atherosclerotic plaque is less
prevalent in African Americans with diabetes relative to European Americans. We explored
ethnicity-speciﬁc relationships between albuminuria and calciﬁed plaque involving the infrare-
nal aorta, coronary artery, and carotid artery in 835 European American and 393 African
American subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Generalized estimating equations with ex-
changeable correlation and the sandwich estimator of the variance were used to test for associ-
ation between the principal component of calciﬁed plaque in the three vascular beds and urine
albumin-to-creatinine ratio (ACR).
RESULTS — Mean SD ages of African American and European American participants were
56.7  9.6 and 61.7  9.1 years, respectively, with diabetes duration of 10.4  7.4 and 10.0 
7.3 years and median urine ACR of 17.5 and 13.4 mg/g. In African American and European
American participants, respectively, median calciﬁed plaque mass scores were 53.5 and 291 for
coronary artery, 3 and 35.5 for carotid artery, and 761 and 3,237 for aorta. With adjustment for
age, sex, glomerular ﬁltration rate, and BMI, albuminuria was signiﬁcantly associated with
calciﬁed plaque in European Americans (P  3.4  10
8) but not in African Americans (P 
0.33), with signiﬁcant ethnic interaction (P  0.01). Ethnic differences in this relationship
persisted after adjustment for blood pressure, smoking, lipids, and use of ACE inhibitors or
angiotensin receptor blockers.
CONCLUSIONS — Albuminuria is strongly associated with severity of calciﬁed plaque in
European Americans with diabetes but not in African Americans. Disparities in this relationship
may contribute to ethnic differences in the rates of cardiovascular disease that are observed in
subjects with type 2 diabetes.
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A
frican Americans have overall
higher rates of type 2 diabetes (1)
and greater risk for diabetes-
associated renal and cardiovascular com-
plicationsrelativetoEuropeanAmericans
(2,3). In contrast, reports from the Veter-
ans Administration and Kaiser Perma-
nente reveal that when given access to
equivalent medical care, African Ameri-
canswithdiabeteshadapproximatelyhalf
the rate of myocardial infarctions as that
seen in European Americans (4,5). In
accordance with this observation, com-
puted tomography (CT)-derived coro-
nary artery calciﬁed plaque (CP) is
markedly lower in African Americans
with and without diabetes relative to Eu-
ropean Americans (6–10). Coronary CP
correlates with the extent of atherosclero-
sisandsubsequentriskforcardiovascular
disease (CVD) events (11). Coronary ar-
tery CP scores also predict the risk for
CVD events in individuals of all ethnic
groups (12) and are higher among pa-
tients with renal disease relative to indi-
viduals without kidney disease who have
known coronary artery disease (13).
CVDremainsthemajorcauseofmor-
bidity and mortality in patients with
chronic kidney disease (CKD) and end-
stage renal disease (2). Among incident
dialysis patients, African Americans had
fewer myocardial infarctions and im-
proved survival relative to European
Americans (14). As individuals with dia-
betes and nephropathy approach end-
stage renal disease, they typically have
albuminuria with falling glomerular ﬁl-
tration rates (GFRs) over several years.
Associations between albuminuria and
coronary artery CP are robust in Euro-
pean Americans and seem to be at least
equivalent to the risk that is associated
with other established CVD risk factors
(15). We hypothesized that ethnic differ-
ences in the relationship between albu-
minuria and atherosclerosis might
contribute to the lower levels of CP that
are widely observed in African Americans
with diabetes.
TheAfricanAmerican-DiabetesHeart
Study(AA-DHS)isassessingethnicdiffer-
ences and inherited factors that contrib-
ute to the development of CP. Herein, we
compare the relationship between albu-
minuria (urine albumin-to-creatinine ra-
tio [ACR]) and CP in the coronary (Cor)
and carotid (Car) arteries and infrarenal
aorta (Aor) in African American and Eu-
ropean American subjects with type 2 di-
abetes. We made use of a principal
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of calciﬁed atherosclerotic plaque in
all three vascular beds. The majority of
AA-DHS participants have preserved re-
nal function, allowing for separation of
the effects of hyperphosphatemia, ure-
mia, and ingestion of phosphate binders
on vascular calciﬁcation.
RESEARCH DESIGN AND
METHODS— Siblingsconcordantfor
type 2 diabetes were recruited from inter-
nal medicine clinics and community ad-
vertising in the Diabetes Heart Study
(DHS) (8). Diabetes was diagnosed after
the age of 34 years in the absence of his-
torical evidence of ketoacidosis. In addi-
tion, 213 unrelated African American
subjects were subsequently recruited in
the AA-DHS using these same diagnostic
criteria, except that type 2 diabetes was
diagnosedaftertheageof30years.Sub-
jects who underwent prior coronary
artery bypass surgery or carotid endar-
terectomy were excluded from this anal-
ysis because it was felt that the CP mass
score in relevant arteries would be af-
fected by these procedures; those with
priormyocardialinfarctionorstrokewere
included. The study was approved by the
institutional review board at the Wake
ForestUniversitySchoolofMedicine,and
all participants provided written in-
formed consent.
Participant examinations were con-
ducted in the General Clinical Research
Center of the Wake Forest University
School of Medicine and included inter-
views for medical history, current
medications and health behaviors, mea-
surements of body size, resting blood
pressure,12-leadelectrocardiogram,fast-
ingbloodsample,andmorningspoturine
collection. Laboratory assays included
urinealbuminandcreatinineforACR,to-
tal cholesterol, LDL, HDL, triglycerides,
A1C, and fasting serum glucose. Renal
function was assessed using serum creat-
inine concentration and Modiﬁcation of
Diet in Renal Disease estimation of GFR.
History of CVD was provided by self-
report and chart review. Hypertension
was deﬁned as self-report of a physician’s
diagnosis, blood pressure 140/90
mmHg, or use of antihypertensive medi-
cations. Antihypertensive medications
were grouped into drug classes, particu-
larly ACE inhibitors (ACEIs) and angio-
tensin receptor blockers (ARBs), medicines
known to reduce urine ACR.
Vascular imaging
CP was measured in the coronary and ca-
rotid arteries and infrarenal abdominal
aorta using single and multidetector CT
systems incorporating a standardized
scanning protocol based on those cur-
rentlyimplementedintheNationalHeart,
Lung, and Blood Institute’s Multi-Ethnic
Study of Atherosclerosis studies, and
these methods have been reported previ-
ously (8,16). Traditionally, the Agatston
score, also called the calcium score, has
been used to report results. However, the
natureofthisscoringsystemaddsnoiseto
the CT measurement of CP compared
with CP volume–based measures (17). In
this report, we used the calcium mass
score (SmartScore; GE Healthcare,
Waukesha, WI), which is derived from
thevolumescorebutinadditionaccounts
for the density of CP on a pixel-by-pixel
basis. Additional scoring parameters in-
cluded a 90-Hounseﬁeld unit threshold
andtwoadjacentpixelstodeﬁnethemax-
imum calciﬁed lesion size, and the pro-
gram accounted for slice thickness.
Statistical methods
A series of generalized estimating equa-
tions assuming exchangeable correlation
and using the empirical estimate of the
variance to adjust for familial correlation
was computed to test for associations be-
tweenurineACRandCP(18).Thenatural
log of (urine ACR  1) was calculated to
minimize the inﬂuence of extremely large
covariatevaluesonparameterestimatesin
these models. The Box-Cox method was
applied to identify the appropriate trans-
formation of each outcome variable that
would best approximate the distribu-
tional assumptions of conditional nor-
mality and homogeneity of variance of
the residuals (19). The natural logs of
(CorCP  1), (CarCP  1), and (AorCP
1)wereanalyzed.Weappliedprincipal
component analysis (PCA) to compute a
linear combination of CorCP, CarCP, and
AorCP that we used as the primary out-
come variable. The principle component
encompasses the burden of calciﬁed ath-
eroscleroticplaqueinthesethreevascular
beds. There is a strong correlation be-
tween the amount of CP in the coronary
arteries, carotid arteries, and aorta of in-
dividuals with diabetes (20). PCA was
conducted using the correlation matrix
instead of the covariance matrix to ac-
count for the differences in measurement
scales between the three variables. The
ﬁrst principal component explained
70% of the total variation observed in
these three variables and is computed as
PCA1_CP  0.6  CarCP  0.5  CorCP
 0.6  AorCP
ThevariablePCA1_CPwascomputedus-
ing the standardized values of CarCP,
CorCP, and AorCP. The Box-Cox trans-
formationthatbestapproximatedthedis-
tributional assumptions of the model was
theinversePCA1_CP,i.e.,(PCA1_CP)
1.
For PCA1_CP, models were adjusted for
age,sex,BMI,andGFR.Subsequentanal-
yses were further adjusted for use of
ACEIs or ARBs, blood pressure, lipid lev-
els, A1C, and smoking. Standard regres-
sion diagnostics for collinearity and
inﬂuence were computed for each model
reported.
RESULTS— Atotalof1,427individu-
alswithtype2diabeteshadcompletedata
for analysis. Of these, 1,008 were Euro-
pean Americans from 445 families and
419 were African Americans from 297
families. Coronary artery bypass grafting
orcarotidendarterectomywasperformed
in 173 European American and 26 Afri-
can American participants, and these in-
dividuals were excluded. Tables 1 and 2
contain demographic and clinical infor-
mation in study participants. Urine ACR
was 30 mg/g in 60.3% of African Amer-
ican and 71.0% of European American
participants, 30–299 mg/g in 29.0% of
AfricanAmericanand23.5%ofEuropean
Americanparticipants,and300mg/gin
10.7% of African American and 5.5% of
European American participants (Table
1). Median Modiﬁcation of Diet in Renal
Disease estimated GFR was 1.34 ml/s in
African American and 1.09 ml/s in Euro-
pean American participants (P value for
ethnic difference 6.3  10
22), with
graded reductions in GFR from nor-
moalbuminuric to overt proteinuric par-
ticipants in both ethnic groups (Table 2).
Coronary CP was detectable in 81.7
and 93.3% of African American and
European American participants, re-
spectively (P value for ethnic difference
1  10
9). Because distributions of CP
mass scores are highly skewed, mean
scores should be interpreted cautiously
and median values are more reﬂective of
central tendency. In African American
subjects, the median CorCP mass score
was 53.5 (mean 697), median CarCP
mass score was 3 (mean 170), median
AorCP mass score was 761 (mean 4,934),
Albuminuria-CVD in African Americans
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SD 230  758). In European American
subjects, the median CorCP mass score
was 291 (mean 1,277), median CarCP
mass score was 35.5 (mean 275), median
AorCP mass score was 3,237 (mean
9,803), and median ACR was 13.4 mg/g
(110  531); these ethnic differences
were highly signiﬁcant (P  8.2  10
11
to 2.39  10
14). Statistically signiﬁcant
and graded increases in median vascular
CP mass score were observed with in-
creasinglevelsofACRinEuropeanAmer-
icans with P values  1.6  10
4, 2.7 
10
4, and 1.0  10
6, respectively, for
AorCP, CorCP, and CarCP using tradi-
tional ACR cut points 30, 30–299, and
300 mg/g to stratify the sample. When
stratiﬁcation was done using quartiles
of urine ACR, P values improved to
4.7  10
7 and 1.2  10
8 for AorCP
and CorCP but decreased to 4.8  10
5
for CarCP. In African Americans, only
CarCP had a signiﬁcant positive rela-
tionship with urine ACR (P  9.6 
10
3 using ACR quartiles, P  5.8 
10
3 using traditional ACR cutoff val-
ues) (Table 2 and supplementary Table
1, available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc09-1253/DC1).
Table 3 focuses on the relationship
between urine ACR and CP, separately in
eachvasculardistributionandfortheﬁrst
principal component of CP. In age-, sex-,
BMI- and GFR-adjusted analyses, signiﬁ-
cantassociationswereseenbetweenurine
ACR with each vascular bed as well as for
the principal component in European
Americans, whereas signiﬁcant relation-
ships were not present in African Ameri-
cans. In addition, signiﬁcant ethnic
differences were observed in the relation-
shipbetweenurineACRandtheprincipal
component for CP (P  0.01) and a trend
for urine ACR with CarCP (P  0.06).
Table 4 reveals the parameter esti-
mate for the relationship between log
urine ACR and the ﬁrst principal compo-
nentforCPacrossthethreevascularbeds,
adjusted for additional covariates includ-
ing ACEIs or ARBs. The log urine ACR
was signiﬁcantly associated with the ﬁrst
principal component for CP in European
Americans (parameter estimate  SEM
0.0387  0.008; P  8.34  10
7),
whereas a signiﬁcant relationship was not
observed in African Americans (parame-
terestimate0.00680.011;P0.54),
and there was a signiﬁcant ethnic interac-
tion(P0.01).TheBox-Coxtransforma-
tion suggested using a decreasing
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therefore, the direction indicated for the
sign of the parameter estimate should be
inverted when one reverts to the original
scale. Ethnic differences in the relation-
ship between sex and CP were also de-
tected (P  0.0001). Although there was
no association between sex and the ﬁrst
principal component for CP in African
Americans (P  0.37), sex was strongly
associated with CP in European Ameri-
cans, with men having greater CP than
women (P  6.4  10
7).
CONCLUSIONS — This report char-
acterized ethnic differences in the rela-
tionship between calciﬁed atherosclerotic
plaque and albuminuria in African Amer-
icans and European Americans with type
2 diabetes and without advanced renal
dysfunction. Albuminuria and kidney
disease are important risk factors for the
development of atherosclerosis (21). Af-
ter adjustment for the covariates of age,
sex, BMI, and GFR, a signiﬁcant and pos-
itive relationship was observed between
albuminuria and CP in European Ameri-
cans but not in African Americans. Con-
sequently, the ethnic difference in this
relationship suggests that lower amounts
of CP in African Americans with diabetes,
with attendant reduced risk for myocar-
dialinfarctionrelativetothatinEuropean
Americans, could be related in part to a
differentialeffectofalbuminuria.Myocar-
dial infarctions occur signiﬁcantly less of-
teninAfricanAmericanpatientsreceiving
renalreplacementtherapycomparedwith
European American patients, and CVD is
theleadingcauseofdeathinsubjectswith
nephropathy (2,14). Our report inten-
tionally examined European American
and African American subjects with dia-
betes and relatively preserved kidney
function, thereby minimizing the poten-
tial effects of exogenous vitamin D and
vitamin D analogs, phosphate binders,
and calcimimetic agents on CP. These
Table 3—Relationship between albuminuria and calciﬁed atherosclerotic plaque
Vascular bed Ethnicity
Adjusted for age and sex Adjusted for age, sex, BMI, and GFR
Main effect
Ethnic
interaction Main effect
Ethnic
interaction
Estimate P Estimate P Estimate P Estimate P
Aorta African American 0.17 5.1  10
2 0.08 0.42 0.13 1.9  10
1 0.11 0.34
European American 0.26 7.3  10
6 0.28 3.5  10
6
Carotid artery African American 0.18 6.0  10
3 0.13 0.12 0.14 7  10
2 0.13 0.06
European American 0.31 1.0  10
9 0.33 1.0  10
10
Coronary artery African American 0.16 1.1  10
2 0.02 0.84 0.11 1.4  10
1 0.05 0.53
European American 0.18 1.0  10
4 0.19 4.7  10
5
First principal component
for aorta, carotid artery,
and coronary artery
CP* African American 0.02 5.8  10
2 0.03 0.03 0.01 3.3  10
1 0.03 0.01
European American 0.04 4.3  10
8 0.04 3.4  10
8
*Box-Cox transformation suggested using a decreasing function of the principal component. Therefore, direction indicated by the sign of the parameter estimate for
relationships between parameters and CP should be inverted when reverting to the original scale.
Table 4—Generalized estimating equation for the ﬁrst principal component of aorta, carotid artery, and coronary artery CP
African American P European American P
Ethnic interaction (African
American: European American)* P
Intercept 1.8343  0.2499 2.15E13 1.5561  0.2234 3.31E12 — —
Log ACR 0.0068  0.0110 0.54 0.0387  0.0079 8.34E07 0.03  0.01 0.01
Age 0.0165  0.0024 0.00 0.0142  0.0018 1.55E15 0.002  0.00 0.54
Female sex 0.0339  0.0379 0.37 0.1460  0.0293 6.4E07 0.18  0.05 0.0001
BMI 0.0019  0.0022 0.37 0.0016  0.0021 0.45 0.0035  0.0029 0.22
Diastolic blood pressure 0.0012  0.0022 0.59 0.0040  0.0017 0.02 0.0039  0.0027 0.14
Systolic blood pressure 0.0006  0.0013 0.63 0.0005  0.0010 0.58 0.0008  0.0015 0.58
Estimated GFR 0.0004  0.0007 0.61 0.0003  0.0008 0.73 0.001  0.0010 0.29
ACEIs or ARBs 0.0921  0.0534 0.08 0.0396  0.0366 0.28 0.005  0.04 0.90
LDL 0.0007  0.0005 0.11 0.0000  0.0004 0.97 0.0005  0.0006 0.38
HDL 0.0009  0.0013 0.49 0.0004  0.0012 0.75 0.001  0.0017 0.49
A1C 0.0016  0.0055 0.77 0.0122  0.0086 0.16 0.008  0.01 0.24
Smoking
Never 0.2050  0.0418 4.69E07 0.1860  0.0369 2.31E07 0.0064  0.0571 0.91
Former 0.1001  0.0473 0.03 0.1250  0.0341 1.23E04 0.0397  0.0605 0.51
Data are estimates  SEM. Box-Cox transformation suggested using a decreasing function of the principal component. Therefore, direction indicated by the sign of
the parameter estimate for relationships between parameters and CP should be inverted when reverting to the original scale. *Except sex comparison, which tests
the interaction between African American women vs. others.
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phatemia may have an impact on risk for
development of subclinical CVD in pa-
tients with advanced nephropathy (22).
A recent report conﬁrmed the lower
risk of CVD in African Americans with
advanced stages of CKD, relative to Euro-
pean Americans (23). There is mounting
evidence that biological differences may
contribute to ethnic differences in risk for
CVD and development of CP with subse-
quent CVD (6–10). Given equal access to
health care, African Americans with type
2 diabetes and CKD face lower risks for
CVD events than European Americans
(4,5,14,23). In the current report, ACEIs,
ARBs, and lipid-lowering medications
were prescribed nearly equally in African
AmericanandEuropeanAmericanpartic-
ipants. Previously, biological factors have
been implicated in ethnic disparities in
the development of kidney failure (24).
EthnicdifferencesinMYH9riskalleledis-
tribution reveal that inherited factors are
capable of causing ethnic differences in
the incidence of common diseases. It re-
mainspossiblethatotherinheritedfactors
contribute to the ethnic differences in
the development of CP relating to
albuminuria.
Markedly lower levels of CP are ob-
served in African American subjects rela-
tive to those in European American
subjects with and without diabetes (6–
10). Although ethnic differences exist in
the presence of CP, the severity of CP is
strongly associated with risk for coronary
events among individuals of all ethnic
groups. In the Multi-Ethnic Study of Ath-
erosclerosis (MESA), Americans of Euro-
pean, African, Hispanic, and Chinese
descent demonstrated equivalent risk for
CVD events based on level of CP (12).
Conventional CVD risk factors may have
ethnic-speciﬁc effects on risk for CP (20).
Therefore, it is important to assess
whetherethnicdifferencesintherelation-
ship between albuminuria and CP exist
because African Americans are known to
develop type 2 diabetes-associated ne-
phropathy with resultant albuminuria
moreoftenthanEuropeanAmericans(2).
In addition, calcium metabolism clearly
differs between African Americans and
European Americans. Although African
Americanstypicallyingestlessdietarycal-
cium than European Americans, they
have denser bone with lower rates of os-
teoporosis and skeletal resistance to the
effects of parathyroid hormone (25). Re-
lated phenomena may prove to be impor-
tant in the development of CP because
vascular endothelial cells assume osteo-
blastic phenotypes and deposit bone ma-
trix in blood vessels.
Albuminuria markedly increases the
riskforCVDinEuropeanAmericanswith
type 2 diabetes (15). The current analyses
emphasize the importance of ethnic dif-
ferences in the effect of albuminuria on
risk for CVD. We studied a population of
subjects with median 8-year durations of
diabetes, and diabetes would be expected
to magnify atherosclerotic vascular dis-
ease. However, there is no a priori reason
to suspect that the relationship between
albuminuriaandCPwouldbedifferentin
African Americans and European Ameri-
canswithoutdiabetes.Studiesinthesein-
dividuals remain to be performed. It is
possible that the lower levels of CP in Af-
rican Americans despite the presence of
similar or more severe conventional CVD
risk factors, as well as the differential ef-
fects of atherosclerotic risk factors on the
amounts of CP, relate to inherited factors
because CorCP is a heritable trait. The
AA-DHS will soon perform mapping by
admixture linkage disequilibrium in an
attempt to detect genes underlying devel-
opment of CP.
Potential weaknesses of this report are
reliance on cross-sectional data, a single
measurement of albuminuria, and inclu-
sion of only subjects with diabetes. Equiva-
lent diabetes durations and similar
prescription of lipid-lowering and
proteinuria-reducing medications in Afri-
canAmericanandEuropeanAmericanpar-
ticipants, as well as consistency of CorCP
scores when contrasted with other reports,
suggestthelackofbias.Albuminuriaisboth
a marker of renal impairment and a sign of
systemic endothelial dysfunction. It seems
likely that the balance between these rela-
tionshipsmaydifferbetweenAfricanAmer-
icans and European Americans. In the
future,itwillbeimportantthatlongitudinal
studiesclarifytherelationshipbetweenclas-
sic and novel CVD risk factors on ethnic
differences in susceptibility to CP. These
analyses need to be performed in subjects
with and without diabetes.
In summary, albuminuria is strongly
associated with CP in European Ameri-
cans with type 2 diabetes but not in Afri-
can Americans with type 2 diabetes.
Ethnic differences in the relationship be-
tween CP and albuminuria may contrib-
ute to the lower levels of CP and reduced
risk for myocardial infarction in African
Americans with diabetes. It remains to be
determined whether interventions that
reduce albuminuria and preserve renal
function will prevent the development of
calciﬁed atherosclerotic plaque and re-
duce CVD rates equally in African Amer-
icans and European Americans with type
2 diabetes.
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